Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients |
| |
| Affiliation: | 1. Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de Las Nieves, Granada, Spain;2. Servicio de Medicina Interna, Hospital Universitario Virgen de Las Nieves, Granada, Spain;3. Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen de Las Nieves, Granada, Spain;4. Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain;5. Departamento Bioquímica, Biología Molecular e Inmunología III, University of Granada, Granada, Spain;6. Departamento de Medicina, University of Granada, Granada, Spain;7. Programa de Doctorado en Biomedicina, University of Granada, Spain |
| |
| Abstract: | BackgroundHuman leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules present, some will be more or less effective in controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may be involved in the protection or susceptibility to COVID-19.MethodsWe studied the polymorphisms in HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one of the largest HLA-typed patient cohort to date.ResultsOur results show that there is no relationship between HLA polymorphisms or haplotypes and susceptibility or protection to COVID-19.ConclusionOur results may contribute to resolve the contradictory data on the role of HLA polymorphisms in COVID-19 infection. |
| |
| Keywords: | HLA polymorphisms COVID-19 SARS-CoV-2 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
